The global Injectable PrEP market size is predicted to grow from US$ 301 million in 2025 to US$ 831 million in 2032; it is expected to grow at a CAGR of 15.8% from 2026 to 2032.

Injectable PrEP refers to HIV pre-exposure prophylaxis administered via parenteral routes?typically intramuscular or subcutaneous injection?most often in long-acting formulations that create a sustained-release ?depot? and maintain protective drug exposure for weeks to months before potential HIV exposure occurs. The core problem it is designed to solve is the real-world implementation gap of oral PrEP: daily or event-driven pill-taking can be difficult to sustain due to adherence burden, refill continuity, privacy constraints, and stigma associated with visible medication use, and missed doses or interruptions can translate into gaps in protection. By shifting prevention from frequent self-managed dosing to periodic clinic- or program-based administration, injectable PrEP aims to improve continuity of coverage, reduce day-to-day behavioral load, and integrate more naturally with testing, follow-up, and broader sexual health services. Historically, injectable PrEP emerged after oral PrEP established efficacy and guidelines, leveraging advances from long-acting HIV treatment technologies?such as micro-/nano-crystal suspensions, stable depot formulations, and aseptic fill-finish?before expanding through regulatory approvals and phased rollout across regions, with service delivery models (visit cadence, workforce training, cold chain, and retention-in-care) becoming a central determinant of real-world uptake. Upstream, injectable PrEP depends on both conventional pharmaceutical inputs and a component-intensive aseptic supply chain: APIs and key intermediates; chemical reagents, solvents, and catalysts; injection-grade excipients (stabilizers, surfactants, buffers, water for injection, and formulation aids as needed); and the packaging/device components required for sterile manufacturing and administration (injectable-grade glass vials or prefilled syringes, elastomer stoppers/plungers, seals, needles and safety injection devices, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish capacity, sterilization validation, temperature-controlled logistics, and compliant quality systems.In 2025, the global production capacity of injectable PrEP reached 150,000 doses, while total sales amounted to 115,700 doses. The average selling price was USD 2,660 per dose, and manufacturers? gross margins ranged between 60% and 70%.

United States market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Injectable PrEP is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Injectable PrEP players cover Gilead Sciences, ViiV Healthcare, Aurobindo, Cipla, Viatris, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?Injectable PrEP Industry Forecast? looks at past sales and reviews total world Injectable PrEP sales in 2025, providing a comprehensive analysis by region and market sector of projected Injectable PrEP sales for 2026 through 2032. With Injectable PrEP sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Injectable PrEP industry.

This Insight Report provides a comprehensive analysis of the global Injectable PrEP landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Injectable PrEP portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Injectable PrEP market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Injectable PrEP and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Injectable PrEP.

This report presents a comprehensive overview, market shares, and growth opportunities of Injectable PrEP market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Cabotegravir
    Lenacapavir
    Other
    Segmentation by Dosing Interval:
    Short-interval Injections
    Monthly Injections
    Quarterly Injections
    Segmentation by Drug Properties:
    Original Drug
    Generic Drug

Segmentation by Application:

    Hospital
    Clinic
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Gilead Sciences
    ViiV Healthcare
    Aurobindo
    Cipla
    Viatris

Key Questions Addressed in this Report

What is the 10-year outlook for the global Injectable PrEP market?
What factors are driving Injectable PrEP market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Injectable PrEP market opportunities vary by end market size?
How does Injectable PrEP break out by Type, by Application?